Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response

Yumin Wu,1,* Weifeng Shi,1,* Honghai Wang,2,* Jiawei Yue,2 Yijie Mao,1 Wei Zhou,1 Xinagmin Kong,1 Qiqiong Guo,1 Lirong Zhang,1 Pengxiao Xu,1 Yuyue Wang1 1Department of Laboratory Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, People’s Republic of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wu Y, Shi W, Wang H, Yue J, Mao Y, Zhou W, Kong X, Guo Q, Zhang L, Xu P, Wang Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	anti-st2 asthma group 2 innate lymphoid cells (ilc2s) cd4+t cells nanoparticle Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/1c9baa697f5f4a2e80b9197b28249d9d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1c9baa697f5f4a2e80b9197b28249d9d
record_format	dspace
spelling	oai:doaj.org-article:1c9baa697f5f4a2e80b9197b28249d9d2021-12-02T13:57:10ZAnti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response1178-2013https://doaj.org/article/1c9baa697f5f4a2e80b9197b28249d9d2020-12-01T00:00:00Zhttps://www.dovepress.com/anti-st2-nanoparticle-alleviates-lung-inflammation-by-targeting-ilc2s--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Yumin Wu,1,* Weifeng Shi,1,* Honghai Wang,2,* Jiawei Yue,2 Yijie Mao,1 Wei Zhou,1 Xinagmin Kong,1 Qiqiong Guo,1 Lirong Zhang,1 Pengxiao Xu,1 Yuyue Wang1 1Department of Laboratory Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, People’s Republic of China; 2Department of Orthopaedics, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, People’s Republic of China*These authors contributed equally to this workCorrespondence:Yuyue WangThe Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, People’s Republic of ChinaEmail wangyuyue1085@126.comBackground: Asthma has been regarded as an inflammatory disease, and group 2 innate lymphoid cells (ILC2s) are implicated in asthma pathogenesis. However, no strategy is available to block ILC2s function. Efficiency is also limited due to the use of systemic or subcutaneous routes of administration. The purpose of this study was to investigate the effects of nanoparticles targeting suppression of tumorigenicity 2 (ST2), which is the ILC2 receptor, to alleviate lung inflammation in the murine model of asthma.Methods: The ultra-small SPIO nanoparticles were firstly synthesized, OVA-induced mice were administered by anti-ST2-conjugated nanoparticles. The inflammatory degree of the lung was investigated by H&E. The percentages of ILC2s and CD4+T cells in bronchoalveolar lavage fluid (BALF) and lung tissue were determined by FACS. Th2-cytokine and OVA-IgE levels were detected by real-time PCR and ELISA, respectively.Results: Treatment with anti-ST2-conjugated nanoparticles significantly alleviated airway inflammation, IL-33 and IL-13 levels and the percentage of CD4+T cells. The percentage of ILC2s was increased, whereas the levels of IL-13 and IL-5 expressed by ILC2s were reduced.Conclusion: In the present study, we demonstrated that anti-ST2-conjugated nanoparticles can efficiently control lung inflammation in OVA-induced mice by reducing the ability of ILC2s to produce IL-5 and IL-13, thereby reducing CD4+T cells. Our study also demonstrated that the nanoparticle delivery system could improve the performance of anti-ST2, which may be used as a strategic tool to expand the current drug market.Keywords: anti-ST2, asthma, group 2 innate lymphoid cells, (ILC2s), CD4+T cells, nanoparticleWu YShi WWang HYue JMao YZhou WKong XGuo QZhang LXu PWang YDove Medical Pressarticleanti-st2asthmagroup 2 innate lymphoid cells (ilc2s)cd4+t cellsnanoparticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 9745-9758 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	anti-st2 asthma group 2 innate lymphoid cells (ilc2s) cd4+t cells nanoparticle Medicine (General) R5-920
spellingShingle	anti-st2 asthma group 2 innate lymphoid cells (ilc2s) cd4+t cells nanoparticle Medicine (General) R5-920 Wu Y Shi W Wang H Yue J Mao Y Zhou W Kong X Guo Q Zhang L Xu P Wang Y Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response
description	Yumin Wu,1,* Weifeng Shi,1,* Honghai Wang,2,* Jiawei Yue,2 Yijie Mao,1 Wei Zhou,1 Xinagmin Kong,1 Qiqiong Guo,1 Lirong Zhang,1 Pengxiao Xu,1 Yuyue Wang1 1Department of Laboratory Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, People’s Republic of China; 2Department of Orthopaedics, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, People’s Republic of China*These authors contributed equally to this workCorrespondence:Yuyue WangThe Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, People’s Republic of ChinaEmail wangyuyue1085@126.comBackground: Asthma has been regarded as an inflammatory disease, and group 2 innate lymphoid cells (ILC2s) are implicated in asthma pathogenesis. However, no strategy is available to block ILC2s function. Efficiency is also limited due to the use of systemic or subcutaneous routes of administration. The purpose of this study was to investigate the effects of nanoparticles targeting suppression of tumorigenicity 2 (ST2), which is the ILC2 receptor, to alleviate lung inflammation in the murine model of asthma.Methods: The ultra-small SPIO nanoparticles were firstly synthesized, OVA-induced mice were administered by anti-ST2-conjugated nanoparticles. The inflammatory degree of the lung was investigated by H&E. The percentages of ILC2s and CD4+T cells in bronchoalveolar lavage fluid (BALF) and lung tissue were determined by FACS. Th2-cytokine and OVA-IgE levels were detected by real-time PCR and ELISA, respectively.Results: Treatment with anti-ST2-conjugated nanoparticles significantly alleviated airway inflammation, IL-33 and IL-13 levels and the percentage of CD4+T cells. The percentage of ILC2s was increased, whereas the levels of IL-13 and IL-5 expressed by ILC2s were reduced.Conclusion: In the present study, we demonstrated that anti-ST2-conjugated nanoparticles can efficiently control lung inflammation in OVA-induced mice by reducing the ability of ILC2s to produce IL-5 and IL-13, thereby reducing CD4+T cells. Our study also demonstrated that the nanoparticle delivery system could improve the performance of anti-ST2, which may be used as a strategic tool to expand the current drug market.Keywords: anti-ST2, asthma, group 2 innate lymphoid cells, (ILC2s), CD4+T cells, nanoparticle
format	article
author	Wu Y Shi W Wang H Yue J Mao Y Zhou W Kong X Guo Q Zhang L Xu P Wang Y
author_facet	Wu Y Shi W Wang H Yue J Mao Y Zhou W Kong X Guo Q Zhang L Xu P Wang Y
author_sort	Wu Y
title	Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response
title_short	Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response
title_full	Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response
title_fullStr	Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response
title_full_unstemmed	Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response
title_sort	anti-st2 nanoparticle alleviates lung inflammation by targeting ilc2s-cd4+t response
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/1c9baa697f5f4a2e80b9197b28249d9d
work_keys_str_mv	AT wuy antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse AT shiw antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse AT wangh antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse AT yuej antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse AT maoy antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse AT zhouw antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse AT kongx antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse AT guoq antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse AT zhangl antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse AT xup antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse AT wangy antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
_version_	1718392308527792128

Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response

Ejemplares similares